• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600594.SS
Share

Guizhou Yibai Pharmaceutical Co., Ltd. Stocks

CN¥ 3.43Last Updated 14.07.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 388.02M

CN¥ 3.43
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Guizhou Yibai Pharmaceutical Co., Ltd. is a Chinese pharmaceutical enterprise that encompasses the full spectrum of activities from researching and developing new drugs to their production and commercialization throughout the country. The company offers a diverse portfolio of medications, available in various dosage forms including capsules, tablets, granules, syrups, liquid injectables (small-volume), lyophilized powder injections, traditional pills, and oral solutions. These therapeutic agents are designed to address a broad range of medical conditions, specifically targeting oncology, cerebrovascular health, respiratory ailments, rheumatic diseases, digestive disorders, pediatric and gynecological illnesses, alongside providing anti-infective, anti-inflammatory, and pain management solutions. Established in 1995, the company maintains its headquarters in Guiyang, China.

Company Valuation

Undervalued
6/7

From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. In particular, the stock is undervalued on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 03:24

Lucid's stock plummeted following news of a possible bankruptcy. At one point, it was down 57%.

15.07.2026 02:16

"The Prisoner's Dilemma": JPMorgan Warns of a Threat to Coinbase and Circle's Profits

15.07.2026 01:24

Inflation data pushed the indices higher. Software developers are under pressure again

15.07.2026 00:57

Biogen shares fell after disappointing data on its Alzheimer's drug

14.07.2026 23:31

Software developers' stocks plummeted following IBM's warning. What's wrong with the sector?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026